Evidence map›Paper›PMID 38613646›Full record

ArticleHistochemistry and cell biology2024

Circ_100549 promotes tumor progression in lung adenocarcinoma through upregulation of BIRC6.

Feifei Chen, Juan Chen, Yuan Yuan, Surong Fang, Jing Xie, Xiaojuan Xu, Zhenhua Yang, Jianzhong Jiang

Abstract read
PubMed Publisher
In one paragraph

Article in Histochemistry and cell biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Feifei Chen *Department of Respiratory Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.
Juan Chen *Department of Respiratory Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.
Yuan YuanDepartment of Respiratory Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.
Surong FangDepartment of Respiratory Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.
Jing XieGeriatrics Department, The Affiliated Yixing Hospital of Jiangsu University, Yixing, 214200, Jiangsu, China.
Xiaojuan XuGeriatrics Department, The Affiliated Yixing Hospital of Jiangsu University, Yixing, 214200, Jiangsu, China.
Zhenhua YangDepartment of Respiratory Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China. yanghuaixie9776@163.com.
Jianzhong JiangGeriatrics Department, The Affiliated Yixing Hospital of Jiangsu University, Yixing, 214200, Jiangsu, China. jiangnuoshi075@163.com.
Nanjing Medical University · CNYixing People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung adenocarcinoma (LUAD) is a subtype of lung cancer with high incidence and mortality globally. Emerging evidence suggests that circular RNAs (circRNAs) exert critical functions in human cancers, including LUAD. CircRNA_100549 (circ_100549) has been reported to be significantly upregulated in non-small cell lung cancer (NSCLC) samples, while its role in modulating LUAD progression remains to be explored. The current study aims at investigating the functional roles of circ_100549 in LUAD and its downstream molecular mechanism. First, we found that the expression of circ_100549 was higher in LUAD cell lines. Loss-of-function assays verified that depletion of circ_100549 repressed LUAD cell proliferation but accelerated cell apoptosis. Furthermore, in vivo experiments demonstrated that silencing of circ_100549 suppressed tumor growth. Subsequently, based on database analysis, we carried out a series of experiments to explore the mechanisms and effects of circ_100549 underlying LUAD progression, including RNA-binding protein immunoprecipitation (RIP), RNA/DNA pull-down, luciferase reporter, and chromatin immunoprecipitation (ChIP) assays. The results indicated that circ_100549 serves as a ceRNA by sponging miR-95-5p to upregulate BPTF expression, thus upregulating BIRC6 expression at a transcriptional level in LUAD. In summary, our study demonstrated that circ_100549 facilitates LUAD progression by upregulating BIRC6 expression.

Indexed as

Adenocarcinoma of LungInhibitor of Apoptosis ProteinsLung NeoplasmsRNA, CircularUp-RegulationAnimalsApoptosisCell ProliferationDisease ProgressionHumansMiceMice, Inbred BALB CMice, NudeUbiquitin-Protein LigasesBIRC6 protein, humanInhibitor of Apoptosis ProteinsRNA, CircularUbiquitin-Protein LigasesBIRC6BPTFhsa_circ_100549Lung adenocarcinoma

Identifiers

PMID38613646
OpenAlexW4394785813

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.